Increased serum p53 antibody levels indicate poor prognosis in colorectal cancer
Author Information
Author(s): U Kressner, B Glimelius, R Bergstrom, L Pahiman, A Larsson, G Lindmark
Primary Institution: University Hospital, Uppsala
Hypothesis
Are serum p53 antibody levels associated with tumor stage and patient survival in colorectal cancer?
Conclusion
Increased serum p53 antibody levels are associated with poorer prognosis in colorectal cancer patients.
Supporting Evidence
- 32% of patients had increased levels of p53 antibodies.
- Patients with increased p53 antibodies had shorter survival times.
- The study found a significant relationship between p53 antibody status and cancer-specific survival time.
- Serum p53 antibody levels increased with more advanced Dukes' stage.
Takeaway
If a patient has high levels of a certain antibody in their blood, it might mean their cancer is more aggressive and they might not live as long.
Methodology
Serum samples were analyzed using an enzyme-linked immunosorbent assay (ELISA) to measure p53 antibody levels before surgery.
Limitations
The prognostic value of p53 antibody levels diminished when adjusted for Dukes' stage in multivariate analysis.
Participant Demographics
Patients were resected for colorectal cancer, with a median follow-up of 6 years.
Statistical Information
P-Value
P = 0.03
Confidence Interval
95% CI 0.78-3.07
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website